**Author details**

Kai Sun1 , Alan Hodges2,3 and Maen Abdelrahim1 \*

1 Houston Methodist Neal Cancer Center, Houston, Texas, United States

2 Houston Methodist Research Institute, Center for Immunotherapy Research, Houston, Texas, United States

3 Texas A&M College of Medicine, Bryan, Texas, United States

\*Address all correspondence to: mabdelrahim@houstonmethodist.org

© 2022 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma DOI: http://dx.doi.org/10.5772/intechopen.106816*

## **References**

[1] Jennison E, Patel J, Scorletti E, Byrne CD. Diagnosis and management of non-alcoholic fatty liver disease. Postgraduate Medical Journal. 2019;**95**(1124):314-322

[2] Wong VW, Wong GL, Choi PC, Chan AW, Li MK, Chan HY, et al. Disease progression of non-alcoholic fatty liver disease: A prospective study with paired liver biopsies at 3 years. Gut. 2010;**59**(7):969-974

[3] McPherson S, Hardy T, Henderson E, Burt AD, Day CP, Anstee QM. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management. Journal of Hepatology. 2015;**62**(5):1148-1155

[4] Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Longterm follow-up of patients with NAFLD and elevated liver enzymes. Hepatology. 2006;**44**(4):865-873

[5] Calzadilla Bertot L, Adams LA. The natural course of non-alcoholic fatty liver disease. International Journal of Molecular Science. 2016;**17**:5

[6] Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clinical Gastroenterology and Hepatology. 2015;**13**:643

[7] Pais R, Charlotte F, Fedchuk L, Bedossa P, Lebray P, Poynard T, et al. A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. Journal of Hepatology. 2013;**59**(3):550-556

[8] Ward ZJ, Bleich SN, Cradock AL, Barrett JL, Giles CM, Flax C, et al. Projected U.S. State-level prevalence of adult obesity and severe obesity. The New England Journal of Medicine. 2019;**381**(25):2440-2450

[9] Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;**67**(1):123-133

[10] Lee SS, Park SH, Kim HJ, Kim SY, Kim M-Y, Kim DY, et al. Non-invasive assessment of hepatic steatosis: Prospective comparison of the accuracy of imaging examinations. Journal of Hepatology. 2010;**52**(4):579-585

[11] Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: A meta-analysis. Hepatology. 2011;**54**(3):1082-1090

[12] Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Targher G, et al. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases. Metabolism. 2017;**72**:57-65

[13] Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002;**123**(3):745-750

[14] Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: Systematic review and meta-analysis.

Clinical Gastroenterology and Hepatology. 2007;**5**(10):1214-1220

[15] Noureddin M, Lam J, Peterson MR, Middleton M, Hamilton G, Le T-A, et al. Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials. Hepatology. 2013;**58**(6):1930-1940

[16] Zhang B, Ding F, Chen T, Xia L-H, Qian J, Lv G-Y. Ultrasound hepatic/ renal ratio and hepatic attenuation rate for quantifying liver fat content. World Journal of Gastroenterology. 2014;**20**(47):17985-17992

[17] Loomba R, Wolfson T, Ang B, Hooker J, Behling C, Peterson M, et al. Magnetic resonance elastography predicts advanced fibrosis in patients with nonalcoholic fatty liver disease: A prospective study. Hepatology. 2014;**60**(6):1920-1928

[18] Ioannou GN. Epidemiology and risk-stratification of NAFLDassociated HCC. Journal of Hepatology. 2021;**75**(6):1476-1484

[19] Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, Hosaka T, et al. Large-Scale Long-Term Follow-Up Study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. The American Journal of Gastroenterology. 2012;**107**(2):253-261

[20] Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, Richardson PA, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;**155**(6):1828

[21] Sørensen HT, Mellemkjaer L, Jepsen P, Thulstrup AM, Baron J, Olsen JH, et al. Risk of cancer in patients hospitalized with fatty liver: A Danish cohort study. Journal of Clinical Gastroenterology. 2003;**36**(4):356-359

[22] White DL, Kanwal F. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clinical Gastroenterology and Hepatology. 2012;**10**(12):1342

[23] Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, Duseja A, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clinical Gastroenterology and Hepatology. 2019;**17**(4):748

[24] Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;**64**(1):73-84

[25] Bhaskaran K, Dos-Santos-Silva I, Leon DA, Douglas IJ, Smeeth L. Association of BMI with overall and cause-specific mortality: A population-based cohort study of 3·6 million adults in the UK. The Lancet Diabetes and Endocrinology. 2018;**6**(12):944-953

[26] Yang JD, Ahmed F, Mara KC, Addissie BD, Allen AM, Gores GJ, et al. Diabetes is associated with increased risk of hepatocellular carcinoma in patients with cirrhosis from nonalcoholic fatty liver disease. Hepatology. 2020;**71**(3):907-916

[27] Welzel TM, Graubard BI, Zeuzem S, El-Serag HB, Davila JA, McGlynn KA. Metabolic syndrome increases the risk of primary liver cancer in the United States: A study in the SEER-Medicare database. Hepatology. 2011;**54**(2):463-471

*Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma DOI: http://dx.doi.org/10.5772/intechopen.106816*

[28] Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: A prospective study. Gastroenterology. 2011;**140**(1):124-131

[29] Rich NE, Hester C, Odewole M, Murphy CC, Parikh ND, Marrero JA, et al. Racial and ethnic differences in presentation and outcomes of hepatocellular carcinoma. Clinical Gastroenterology and Hepatology. 2019;**17**(3):551

[30] Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, Dufour JF, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology. 2014;**61**(1):75-81

[31] Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: Current concepts and future challenges. Nature Reviews. Gastroenterology & Hepatology. 2019;**16**(7):411-428

[32] Marra F, Svegliati-Baroni G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. Journal of Hepatology. 2018;**68**(2):280-295

[33] Hatting M, Tacke F. From NAFLD to HCC: Is IL-17 the crucial link? Hepatology. 2017;**65**(2):739-741

[34] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: Trends, predictions, risk factors and prevention. Nature Reviews. Gastroenterology & Hepatology. 2021;**18**(4):223-238

[35] Pinyol R, Torrecilla S, Wang H, Montironi C, Pique-Gili M,

Torres-Martin M, et al. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. Journal of Hepatology. 2021;**75**(4):865-878

[36] Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology. 1998;**114**(4):842-845

[37] Lambert JE, Ramos-Roman MA, Browning JD, Parks EJ. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology. 2014;**146**(3):726-735

[38] Sunny NE, Bril F, Cusi K. Mitochondrial adaptation in nonalcoholic fatty liver disease: Novel mechanisms and treatment strategies. Trends in Endocrinology and Metabolism. 2017;**28**(4):250-260

[39] Sydor S, Best J, Messerschmidt I, Manka P, Vilchez-Vargas R, Brodesser S, et al. Altered microbiota diversity and bile acid signaling in cirrhotic and noncirrhotic NASH-HCC. Clinical and Translational Gastroenterology. 2020;**11**(3):e00131

[40] Yu YC, Luu HN, Wang R, Thomas CE, Glynn NW, Youk AO, et al. Serum biomarkers of iron status and risk of hepatocellular carcinoma development in patients with nonalcoholic fatty liver disease. Cancer Epidemiology, Biomarkers & Prevention. 2022;**31**(1):230-235

[41] Ringelhan M, Pfister D, O'Connor T, Pikarsky E, Heikenwalder M. The immunology of hepatocellular carcinoma. Nature Immunology. 2018;**19**(3):222-232

[42] Luther J, Garber JJ, Khalili H, Dave M, Bale SS, Jindal R, et al. Hepatic injury in nonalcoholic steatohepatitis contributes to altered intestinal

permeability. Cellular and Molecular Gastroenterology and Hepatology. 2015;**1**(2):222-232

[43] Ehling J, Bartneck M, Wei X, Gremse F, Fech V, Mockel D, et al. CCL2 dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut. 2014;**63**(12):1960-1971

[44] Lei L, Ei Mourabit H, Housset C, Cadoret A, Lemoinne S. Role of angiogenesis in the pathogenesis of NAFLD. Journal of Clinical Medicine. 2021;**10**(7):1960-1971

[45] Cabia B, Andrade S, Carreira MC, Casanueva FF, Crujeiras AB. A role for novel adipose tissue-secreted factors in obesity-related carcinogenesis. Obesity Reviews. 2016;**17**(4):361-376

[46] Carlessi R, Kohn-Gaone J, Olynyk JK, Tirnitz-Parker JEE. Mouse models of hepatocellular carcinoma. In: Tirnitz-Parker JEE, editor. Hepatocellular Carcinoma. Brisbane (AU): Codon Publications; 2019

[47] Tanaka S, Miyanishi K, Kobune M, Kawano Y, Hoki T, Kubo T, et al. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma. Journal of Gastroenterology. 2013;**48**(11):1249-1258

[48] Nishida N, Yada N, Hagiwara S, Sakurai T, Kitano M, Kudo M. Unique features associated with hepatic oxidative DNA damage and DNA methylation in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology. 2016;**31**(9):1646-1653

[49] Cornell L, Munck JM, Alsinet C, Villanueva A, Ogle L, Willoughby CE, et al. DNA-PK-A candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to

treatment and survival. Clinical Cancer Research. 2015;**21**(4):925-933

[50] Zucman-Rossi J, Villanueva A, Nault JC, Llovet JM. Genetic landscape and biomarkers of hepatocellular carcinoma. Gastroenterology. 2015;**149**(5):1226

[51] European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology. 2018;**69**(1):182-236

[52] Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. Journal of Hepatology. 2022;**76**(2):446-457

[53] Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. The New England Journal of Medicine. 2008;**359**(4):378-390

[54] Cheng A-L, Kang Y-K, Chen Z, Tsao C-J, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebocontrolled trial. The Lancet Oncology. 2009;**10**(1):25-34

[55] Bruix J, Raoul J-L, Sherman M, Mazzaferro V, Bolondi L, Craxi A, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. Journal of Hepatology. 2012;**57**(4):821-829

[56] Bruix J, Cheng A-L, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of

*Non-alcoholic Fatty Liver Disease Associated Hepatocellular Carcinoma DOI: http://dx.doi.org/10.5772/intechopen.106816*

sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. Journal of Hepatology. 2017;**67**(5):999-1008

[57] Howell J, Samani A, Mannan B, Hajiev S, Aval LM, Abdelmalak R, et al. Impact of NAFLD on clinical outcomes in hepatocellular carcinoma treated with sorafenib: An international cohort study. JCO. 2021;**39**(3):289

[58] Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. The Lancet. 2018;**391**(10126):1163-1173

[59] Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, et al. Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: Multicenter retrospective study. Scientific Reports. 2021;**11**(1):16663

[60] Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebocontrolled, phase 3 trial. The Lancet. 2017;**389**(10064):56-66

[61] Zhu AX, Park JO, Ryoo B-Y, Yen C-J, Poon R, Pastorelli D, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. The Lancet Oncology. 2015;**16**(7):859-870

[62] Abou-Alfa GK, Meyer T, Cheng A-L, El-Khoueiry AB, Rimassa L, Ryoo B-Y, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. The New England Journal of Medicine. 2018;**379**(1):54-63

[63] El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 2017;**389**(10088):2492-2502

[64] Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. The Lancet Oncology. 2018;**19**(7):940-952

[65] Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim HY, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. Journal of Clinical Oncology. 2020;**38**(3):193-202

[66] Yau T, Park J-W, Finn RS, Cheng A-L, Mathurin P, Edeline J, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, openlabel, phase 3 trial. The Lancet Oncology. 2022;**23**(1):77-90

[67] Yau T, Kang Y-K, Kim T-Y, El-Khoueiry AB, Santoro A, Sangro B, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The CheckMate 040 Randomized Clinical Trial. JAMA Oncology. 2020;**6**(11):e204564

[68] Dual Immunotherapy Makes Strides against HCC. Cancer Discovery. 2022;**12**(4). Available from:

https://aacrjournals.org/cancerdiscovery/ article/12/4/OF1/689618/Dual-Immunotherapy-Makes-Strides-against-HCCDual

[69] Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. The New England Journal of Medicine. 2020;**382**(20):1894-1905

[70] Pfister D, Nunez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, et al. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature. 2021;**592**(7854):450-456

**Chapter 3**
